Investigating best practices for MicroPulse transscleral therapy for glaucoma
January 12, 2022
Robert J. Noecker, MD, MBA, discusses the IRIDEX consensus paper regarding MicroPulse transscleral therapy for glaucoma at AAO 2021.
© 2022 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
Expert Interviews
Delving into ancillary testing frequency based on the IRIS registry
January 14, 2022
Dr Ted Leng discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.
Bimatoprost implant successfully lowers IOP in Phase 3 of the ARTEMIS study
December 29, 2021
At AAO, AbbVie presented results from the ARTEMIS study, showcasing IOP lowering that extends beyond the original 20-month timeframe.
Updates on brolucizumab for treatment of wet AMD and DMO
December 23, 2021
Dr Jill Hopkins discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular oedema.
Shedding light on antibiotic resistance in ophthalmology with ARMOR study data
December 20, 2021
At the 2021 American Academy of Ophthalmology annual meeting, Dr Penny Asbell discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.
Phase 1 study results for new sustained-release anti-VEGF formulation, EYP-1901
December 10, 2021
Dr Jay Duker discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.
Phase 2b study results of AR-15512 for the treatment of dry eye
November 29, 2021
At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a TRPM8 antagonist, for the treatment of dry eye.
Presbyopia-correcting drops provide hope for frustrated patients
November 14, 2021
Dr Cathleen McCabe describes how VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, provides opportunities for patients looking for spectacle independence.
President John Saharek on the ImprimisRx pipeline, details 3 products
November 12, 2021
ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.
5-year followup data for study on combining anterior and posterior segment surgery
November 10, 2021
Dr Timothy G. Murray discusses the 5-year followup data from a large, consecutive case series of combined anterior and posterior segment surgery and the benefits of a single procedure for the recovery of vision and decreased risk.